Clinical trials · South Carolina
Neovascular Age-related Macular Degeneration clinical trials in South Carolina
We’re tracking 15 recruiting neovascular age-related macular degeneration studies with a site in South Carolina — including Phase 1/Phase 2, Phase 2, Phase 2/Phase 3, Phase 3 and Phase 4 studies, each written for real people, not researchers.
Recruiting studies in South Carolina
- NCT06659445RecruitingPhase 2
Study of ONL1204 for geographic atrophy in dry AMD
This study tests an investigational medicine called ONL1204 given as an injection into the eye for people with a form of advanced dry age-related macular degeneration called geographic atrophy. The goal is to see if it can slow vision loss.
Mt. Pleasant, South CarolinaAges 55 years+ - NCT07614776RecruitingPhase 3
New Eye Injection Treatment for Age-Related Macular Degeneration
This study tests whether a new eye injection called ABP 938 works as well as or better than the current standard treatment (Eylea) for wet age-related macular degeneration—a condition that causes vision loss in the center of your sight. You would receive injections into your eye every month for a year.
Beaufort, South CarolinaAges 50 years+ - NCT07440225RecruitingPhase 2/Phase 3
Testing a new drug for wet macular degeneration
This trial tests a new medicine called EYE201/MK-8748 for people who have wet age-related macular degeneration (a condition where abnormal blood vessels grow under the retina). It's for those who haven't had treatment before and were diagnosed recently.
Aiken, South CarolinaAges 50 years+ - NCT05197270RecruitingPhase 1/Phase 2
Gene therapy for wet age-related macular degeneration
This study tests a new gene therapy called 4D-150 for people with wet age-related macular degeneration (AMD). It aims to reduce the need for frequent anti-VEGF injections by delivering a long-lasting treatment into the eye.
West Columbia, South CarolinaAges 50 years+ - NCT07007065RecruitingPhase 3
Study of a gene therapy for wet age-related macular degeneration
This trial tests a one-time gene therapy injection for wet AMD that may reduce the need for regular eye injections. It is for people who have already responded to anti-VEGF injections but want a longer-lasting treatment.
Bluffton, South CarolinaAges 50 years+ - NCT06541704RecruitingPhase 3
Study of pozelimab with cemdisiran for geographic atrophy
This trial tests a combination of two study drugs (pozelimab and cemdisiran) given as a shot under the skin to slow the progression of geographic atrophy, a type of advanced dry age-related macular degeneration that causes blind spots in central vision.
Greenville, South CarolinaAges 50–85 - NCT04853251RecruitingPhase 4
Study of corneal cells after a ranibizumab eye implant
This trial checks how well corneal endothelial cells (cells that help keep the cornea clear) do in people with neovascular age-related macular degeneration (nAMD) who are treated with a port-delivery implant that releases ranibizumab. It also helps doctors understand whether this method changes corneal health and stays safe while controlling the eye disease.
Florence, South CarolinaAges 50 years+ - NCT07496567RecruitingPhase 2/Phase 3
Study of EYE201 for wet age-related macular degeneration
This trial tests a new medicine, EYE201, for people with wet age-related macular degeneration (AMD) that has not been treated before. The study will see if this drug can help improve vision and slow down vision loss.
Beaufort, South CarolinaAges 50 years+ - NCT07516132RecruitingPhase 3
Long-term safety study of axitinib implant for wet macular degeneration
This study follows people who completed an earlier 2-year trial of OTX-TKI, a small implant placed in the eye to treat wet age-related macular degeneration (a condition causing vision loss). Researchers want to make sure the treatment remains safe over time.
West Columbia, South CarolinaAges 50 years+ - NCT07215390RecruitingPhase 2
Study of APL-3007 plus Syfovre for geographic atrophy
This trial tests whether a new drug called APL-3007, when added to your current Syfovre treatment, can slow the progression of geographic atrophy (an advanced form of dry age-related macular degeneration). It's for people who have already been on Syfovre for at least 6 months.
Mt. Pleasant, South CarolinaAges 60 years+ - NCT03683251RecruitingPhase 3
Extension study for a refillable eye implant plus ranibizumab
This trial studies whether continuing treatment with a refillable eye implant (Port Delivery System) and ranibizumab injection helps control a specific type of wet macular degeneration. It’s mainly for people who already finished an earlier related study and are able to keep up with frequent eye checks and procedures.
Florence, South CarolinaAges 50 years+ - NCT07630649RecruitingPhase 2
Gene therapy for wet age-related macular degeneration in second eye
This study tests a one-time gene therapy injection (ixoberogene soroparvovec) in the second eye of people with wet age-related macular degeneration who have already responded well to anti-VEGF injections. The goal is to see if this gene therapy can help preserve or improve vision in that eye.
West Columbia, South CarolinaAges 50 years+ - NCT07482176RecruitingPhase 3
Gene therapy trial for wet age-related macular degeneration
This trial tests a one-time gene therapy injection (IXO-vec) for people with wet age-related macular degeneration (nAMD). It aims to reduce the need for frequent eye injections by helping the eye make its own medicine to block the growth of harmful blood vessels.
Bluffton, South CarolinaAges 50 years+ - NCT07064759RecruitingPhase 3
Gene therapy injection for wet age-related macular degeneration
This trial tests a one-time gene therapy injection (4D-150) for wet AMD. It might help reduce the need for frequent anti-VEGF eye injections by targeting the underlying cause of new blood vessel growth.
Mt. Pleasant, South CarolinaAges 50 years+ - NCT07205887RecruitingPhase 2
Study of EYE103 for wet AMD or macular edema after BRVO
This trial tests an investigational drug called EYE103 injected into the eye to treat two conditions: wet age-related macular degeneration (AMD) or macular edema following a branch retinal vein occlusion (BRVO). It looks at how safe and effective the drug is for people who have not had treatment before or have not responded well to previous treatments.
West Columbia, South CarolinaAges 18 years+
Neovascular Age-related Macular Degeneration trials by city in South Carolina
Where these studies are running in South Carolina
Institutions with a site for the recruiting neovascular age-related macular degeneration studies listed above.
- Palmetto Retina Center · 10 studies
- Charleston Neuroscience Institute · 8 studies
- Retina Consultants of Carolina · 2 studies
- Retina Consultants of South Carolina · 2 studies
- Adverum Clinical Site 222
- Adverum Clinical Site 241
- Adverum site 122
- Carolina Eyecare Physicians
What taking part in a neovascular age-related macular degeneration study involves
A screening visit first
Before anything else, the study team checks whether you fit — usually a visit with some tests. You can stop at any point, and screening is typically free.
Care at a nearby site
Study visits happen at a clinic or hospital taking part. Many studies cover the cost of the study treatment and related visits, and some reimburse travel.
You stay in control
Taking part is voluntary and you can leave a study at any time, for any reason, without affecting your regular care.
The team decides eligibility
Our fit check is a helpful first read, not a decision. The study team makes the final call after reviewing your health history.
Neovascular Age-related Macular Degeneration trials in other states
Common questions
- Are there neovascular age-related macular degeneration clinical trials in South Carolina?
- Yes. We're currently tracking 15 recruiting neovascular age-related macular degeneration studies with a site in South Carolina, each rewritten in plain language so you can see what it's testing and who it's for.
- How do I find out if I qualify for a neovascular age-related macular degeneration study in South Carolina?
- Each study lists its eligibility rules — age, diagnosis, prior treatments. On every trial page we explain these in plain language and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Do I have to live in South Carolina to take part?
- Not necessarily. These studies have a site in South Carolina, but eligibility is about your health, not your address — some people travel to take part, and a few studies reimburse travel. The study team can tell you what's required.
- Does it cost anything to join a neovascular age-related macular degeneration trial?
- Using Clin2 is always free. Many trials cover the study treatment and related visits; some reimburse travel. The study team explains exactly what's covered before you decide.
Not the right time?
New neovascular age-related macular degeneration studies open in South Carolina regularly. Set up a health profile and we’ll quietly watch for studies that fit you and email you when one opens.
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.